Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Pharmaceutical Safety Bureau Earmarks 230 Mil. Yen for New Guidelines Initiative
December 26, 2016
- MHLW’s FY2017 Budget Up 1.2% at 30.7 Trillion Yen
December 26, 2016
- MHLW to Set Up MID-NET Usage Fees to Induce Drug Makers to Use It for PMS: Official
December 26, 2016
- AMED’s FY2017 Budget Earmarks 126.5 Billion Yen for Medical R&D
December 26, 2016
- Govt’s FY2017 Budget Includes 32 Trillion Yen for Social Security Spending
December 26, 2016
- PM Abe’s Panel to Keep Vigilant Eyes on Drug Prices, Reimbursement Fees
December 22, 2016
- Chuikyo to Discuss Annual Price Revision Plan in Concert with CEFP: Official
December 22, 2016
- Claims for Health Damage Compensation Continued to Increase in FY2015, Rising to 1,566: PMDA
December 22, 2016
- Blanket Driving Ban for 3 SNRIs Eased: MHLW
December 21, 2016
- MHLW Begins Drafting Manual on Proper Use of Antibiotics for Clinicians
December 21, 2016
- Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
December 21, 2016
- Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
- Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
- MHLW OKs Tecfidera, Otezla, Other Drugs
December 20, 2016
- Natural Rise in Social Security Spending to Be Curbed to 500 Billion Yen
December 20, 2016
- Govt Clarifies Its Goals in Healthcare R&D Plan, Aims to Begin Clinical Trials for iPS-Based Therapies by 2020
December 19, 2016
- Chuikyo Kicks Off Debates on 2018 Dual Reform of Healthcare and Long-Term Care Insurance
December 15, 2016
- HIV Med Descovy OK’ed for NHI Price Listing on Dec. 21
December 15, 2016
- PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
- MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…